Roche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection

Elecsys ® HBeAg quant is an immunoassay that can be used as an early marker of acute hepatitis B infection, as well as an indicator of chronic active hepatitis in combination with other laboratory results and clinical information.The single test will inform clinicians if treatment is required and regimens are working in conjunction with other diagnostic assays.Almost 300 million people globally have chronic hepatitis B, causing a significant burden to health systems as it puts patients at high risk of death from cirrhosis and liver cancer.1Basel, 27 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of Elecsys ® HBeAg quant, an immunoassay that is able to determine both the presence and quantity (qualitative and quantitative) of the hepatitis B e antigen (HBeAg) in human serum and plasma. This launch means that, when combined with other laboratory results and clinical information, patients will now get c onfirmation on whether they have hepatitis B (HBV), and if so, to what extent, as well as treatment monitoring through one single assay. It is for use on the cobas® e analysers in countries accepting the CE Mark. HBV is the most common type of viral hepatitis affecting people of all ages, posing a significant burden on people and healthcare systems globally.1The new Elecsys HBeAg quant test will complement existing HBV testing markers. When a patient with suspected HBV returns a positive result of HBeAg, clinicians can determine the patient ’s ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news